plumbagin has been researched along with Nasopharyngeal Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, X; Liao, Y; Liu, F; Nie, L; Pan, Q; Su, M; Yang, L | 1 |
| Chen, L; Feng, L; Gou, J; Gu, X; Li, B; Li, L; Li, T; Wang, L; Wu, M; Yang, J; Zhang, K; Zhao, Y; Zhu, L | 1 |
2 other study(ies) available for plumbagin and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
In silico analysis and experimental validation to exhibit anti-nasopharyngeal carcinoma effects of plumbagin, an anti-cancer compound.
Topics: Humans; Molecular Docking Simulation; Naphthoquinones; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Plumbagin inhibits the proliferation of nasopharyngeal carcinoma 6-10B cells by upregulation of reactive oxygen species.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Glycogen Synthase Kinase 3 beta; Humans; M Phase Cell Cycle Checkpoints; Naphthoquinones; Nasopharyngeal Carcinoma; Oxidation-Reduction; Reactive Oxygen Species; STAT3 Transcription Factor; Up-Regulation | 2018 |